NASDAQ:CASI - CASI Pharmaceuticals Stock Price, Forecast & News

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

CASI Pharmaceuticals Inc (NASDAQ:CASI) announced its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The biotechnology company had revenue of $2.79 million for the quarter, compared to the consensus estimate of $0.70 million. View CASI Pharmaceuticals' Earnings History.

CASI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for CASI Pharmaceuticals.

1 Wall Street analysts have issued 1-year price objectives for CASI Pharmaceuticals' shares. Their forecasts range from $7.00 to $7.00. On average, they expect CASI Pharmaceuticals' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 228.6% from the stock's current price. View Analyst Price Targets for CASI Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CASI Pharmaceuticals.

Media headlines about CASI stock have trended very positive this week, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CASI Pharmaceuticals earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for CASI Pharmaceuticals.

CASI Pharmaceuticals saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 2,840,000 shares, a decline of 5.0% from the January 15th total of 2,990,000 shares. Based on an average daily volume of 108,300 shares, the days-to-cover ratio is currently 26.2 days. Currently, 7.5% of the company's stock are short sold. View CASI Pharmaceuticals' Current Options Chain.

Some companies that are related to CASI Pharmaceuticals include Cellectis (CLLS), Oyster Point Pharma (OYST), Proteon Therapeutics (PRTO), Atara Biotherapeutics (ATRA), Avrobio (AVRO), Aptose Biosciences (APTO), GENFIT S A/ADR (GNFT), Rubius Therapeutics (RUBY), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), MeiraGTx (MGTX), Replimune Group (REPL), Nantkwest (NK), Prevail Therapeutics (PRVL) and Compugen (CGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include Caladrius Biosciences (CLBS), Frontier Communications (FTR), Celsion (CLSN), Catalyst Pharmaceuticals (CPRX), InterDigital Wireless (IDCC), Bank of Hawaii (BOH), Energy Transfer LP Unit (ET), Novavax (NVAX), Progenics Pharmaceuticals (PGNX) and Rigel Pharmaceuticals (RIGL).

CASI Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include IDG Accel China Growth Fund III Associates L.P. (8.28%), Wellington Shields & Co. LLC (1.33%), State Street Corp (0.99%), Charles Schwab Investment Management Inc. (0.31%), California Public Employees Retirement System (0.13%) and Vident Investment Advisory LLC (0.07%). Company insiders that own CASI Pharmaceuticals stock include Brian D Coleman, China Growth Fund Idg-Accel II and Wei-Wu He. View Institutional Ownership Trends for CASI Pharmaceuticals.

CASI stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Bank of America Corp DE. View Insider Buying and Selling for CASI Pharmaceuticals.

CASI stock was acquired by a variety of institutional investors in the last quarter, including IDG Accel China Growth Fund III Associates L.P., Wellington Shields & Co. LLC, State Street Corp, Zebra Capital Management LLC, Charles Schwab Investment Management Inc., Barclays PLC, UBS Group AG and Vident Investment Advisory LLC. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Brian D Coleman, China Growth Fund Idg-Accel II and Wei-Wu He. View Insider Buying and Selling for CASI Pharmaceuticals.

Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CASI stock can currently be purchased for approximately $2.13.

CASI Pharmaceuticals has a market capitalization of $205.23 million. The biotechnology company earns $-27,470,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. CASI Pharmaceuticals employs 124 workers across the globe.View Additional Information About CASI Pharmaceuticals.

The official website for CASI Pharmaceuticals is http://www.casipharmaceuticals.com/.

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]